Breast cancer can be categorized based on the presence or absence of specific molecular markers: hormone (progesterone or estrogen) receptor (HR) positive/human epidermal growth factor-2 (HER2)-negative (70% of patients); HER2-positive (15–20%); and lastly triple-negative breast cancers (~15%) [3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.